Vedolizumab (trade name Entyvio) has been approved since May 2014 for the treatment of patients suffering from moderate to severe form of Crohn's disease or ulcerative colitis. The Institute for Quality and Efficiency in Health Care (IQWiG) has conducted an early benefit assessment pursuant to the Pharmaceutical Market Restructuring Act (AMNOG) to determine whether the drug compared with to appropriate comparator therapy offers an additional benefit in these patient populations. Such an additional benefit has not been demonstrated, since the dossier for these two diseases contained no appropriate data.

For more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/zusatznutzen-von-vedolizumab-ist-nicht-belegt.6354.html?&et_cid=4&et_lid=%25208 [German]